Table 3.
Univariate analysis of patient and tumor characteristics associated with pCR (ypT0/isN0) versus incomplete pathologic primary tumor and axillary lymph node response to NCT
| Characteristic | pCR | Incomplete response | Univariate p value | Multivariate p value | Multivariate OR (95 % CI) |
|---|---|---|---|---|---|
| All patients | 173 (28 %) | 435 (72 %) | |||
| Patient age | |||||
| ≤50 years | 81 (29 %) | 199 (71 %) | 0.811 | ||
| >50 years | 92 (28 %) | 236 (72 %) | |||
| IHC ER status at diagnosisa | |||||
| Positive | 65 (18 %) | 299 (82 %) | <0.001 | ||
| Negative | 107 (44 %) | 135 (56 %) | |||
| PR status at diagnosisa | |||||
| Positive | 38 (13 %) | 252 (87 %) | <0.001 | 0.025 | 0.51 (0.28, 0.92) |
| Negative | 134 (42 %) | 182 (58 %) | Ref. | ||
| HER2 status at diagnosisa | |||||
| Positive | 84 (42 %) | 117 (58 %) | <0.001 | <0.001 | 2.70 (1.72, 4.21) |
| Negative | 88 (22 %) | 316 (78 %) | Ref. | ||
| Grade at diagnosisa | |||||
| 1 | 1 (4 %) | 24 (96 %) | <0.001 | 0.025 | 0.22 (0.03, 1.80) |
| 2 | 34 (18 %) | 154 (82 %) | 0.52 (0.30, 0.88) | ||
| 3 | 134 (35 %) | 250 (65 %) | Ref. | ||
| T stage | |||||
| T1 | 22 (28 %) | 56 (72 %) | 0.046 | ||
| T2 | 119 (32 %) | 255 (68 %) | |||
| T3 | 25 (19 %) | 108 (81 %) | |||
| T4 | 7 (30 %) | 16 (70 %) | |||
| Initial lymph node statusa | |||||
| Negative | 90 (39 %) | 138 (61 %) | <0.001 | <0.001 | 2.08 (1.36, 3.21) |
| Positive | 78 (22 %) | 279 (78 %) | Ref. | ||
| BluePrint-subtype status | |||||
| Non-Luminal | 153 (43 %) | 206 (57 %) | <0.001 | <0.001 | 4.21 (2.10, 8.42) |
| Luminal | 20 (8 %) | 229 (92 %) | Ref. | ||
| MammaPrint | |||||
| Low Risk | 5 (7 %) | 63 (93 %) | <0.001 | ||
| High Risk | 168 (31 %) | 372 (69 %) |
pCR pathologic complete response, NCT neoadjuvant chemotherapy, OR odds ratio, CI confidence interval, IHC immunohistochemistry, PR progesterone receptor, ER estrogen receptor
aIncluded in multivariate modeling of dichotomized tumor size and molecular subtype